LIMINATUS PHARMA, INC. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
LIMINATUS PHARMA, INC. (LIMN) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 36.93 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2026-08-14
- LIMINATUS PHARMA, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2026-03-31 was 19.60M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month |
|---|---|---|---|---|
| 2026-06-30 | 36.93M shares 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | 19.60M shares S-1 · filed 2026-06-24 | |||
| 2025-12-31 | 6.74M shares S-1 · filed 2026-06-24 | |||
| 2025-09-30 | 6.74M shares 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | 7.74M shares 10-Q · filed 2025-10-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |